Log In
BCIQ
Print this Print this
 

StrataGraft

  Manage Alerts
Collapse Summary General Information
Company Mallinckrodt plc
DescriptionSecond-generation cell-based, tissue-engineered human skin substitute developed using NIKS human keratinocytes
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Organ/tissue engineering
Latest Stage of DevelopmentPhase III
Standard IndicationWounds
Indication DetailsPromote healing of the deep partial-thickness component of complex skin defects; Treat partial and full-thickness skin burns; Treat severe second-degree burns; Treat severe, deep partial thickness burns; Treat severe, full thickness burns
Regulatory Designation U.S. - Orphan Drug (Treat partial and full-thickness skin burns)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/31/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today